Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

BACKGROUND: Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepatocell...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Aliment Pharmacol Ther
المؤلفون الرئيسيون: Scheiner, Bernhard, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Koch, Sandra, Schwabl, Philipp, Hinrichs, Jan B., Waneck, Fredrik, Waidmann, Oliver, Reiberger, Thomas, Müller, Christian, Sieghart, Wolfgang, Trauner, Michael, Weinmann, Arndt, Wege, Henning, Trojan, Jörg, Peck‐Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley and Sons Inc. 2019
الموضوعات:
Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593858/
https://ncbi.nlm.nih.gov/pubmed/30980420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15245
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة